Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Exploring Exelon Alzheimer Prevention, Lewy Body Dementia Claims

Executive Summary

Novartis has completed enrollment in a study to examine whether Exelon delays progression from mild cognitive impairment to Alzheimer's disease.

You may also be interested in...



FDA Considering Mild Cognitive Impairment As Distinct Claim For CNS Drugs

Treatment claims for mild cognitive impairment may require distinguishing the syndrome as a separate diagnostic entity from early-onset Alzheimer's disease, FDA suggested in briefing documents for a March 13 meeting of the Peripheral and Central Nervous System Drugs Advisory Committee.

FDA Considering Mild Cognitive Impairment As Distinct Claim For CNS Drugs

Treatment claims for mild cognitive impairment may require distinguishing the syndrome as a separate diagnostic entity from early-onset Alzheimer's disease, FDA suggested in briefing documents for a March 13 meeting of the Peripheral and Central Nervous System Drugs Advisory Committee.

Novartis Exelon Clears FDA For Alzheimer's; Study Vs. Aricept Planned

Novartis plans to initiate a comparative trial of Exelon versus Pfizer/Eisai's Aricept in patients with mild to moderate Alzheimer's disease by the end of the year.

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel